Upgrade to SI Premium - Free Trial

BTIG Downgrades Teva Pharma (TEVA) to Neutral

November 16, 2016 7:33 AM
BTIG downgraded Teva Pharma (NYSE: TEVA) from Buy to Neutral and removed its price target. Analyst Timothy Chiang noted Copaxone ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View Downgrades

Next Articles